Crescent Biopharma
CBIO
77 hedge funds and large institutions have $567M invested in Crescent Biopharma in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 14 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
32% more capital invested
Capital invested by funds: $428M → $567M (+$139M)
25% more call options, than puts
Call options by funds: $826K | Put options by funds: $660K
0.01% more ownership
Funds ownership: 1.05% → 1.05% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 81 → 77 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.18M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.86M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$1.57M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.06M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.37M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.74M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.5M |
| 5 |
Citigroup
New York
|
-$1.18M |
CBIO Hedge Fund Activity: Q1 2019 in Review
77 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2019, worth a combined $567M — up 32% from $428M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CBIO and 10 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 33 added.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $6.27M. The largest seller was Wellington Management Group, cutting an estimated $4.06M.
- 77 institutional investors held Crescent Biopharma (CBIO) as of Q1 2019, down from 81 in Q4 2018.
- Funds reported $567M of Crescent Biopharma stock for Q1 2019, up 32% quarter-over-quarter.
- 10 funds opened new Crescent Biopharma positions in Q1 2019 and 14 closed out, a net change of -4 holders.
- The largest Crescent Biopharma buyer in Q1 2019 was Sectoral Asset Management, an estimated $6.27M added.
- The largest Crescent Biopharma seller in Q1 2019 was Wellington Management Group, an estimated $4.06M sold.
Based on aggregated 13F filings for Q1 2019.